LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.

    Tobaiqy, Mansour / Elkout, Hajer

    International journal of clinical pharmacy

    2024  Volume 46, Issue 2, Page(s) 488–495

    Abstract: Background: Semaglutide, liraglutide and tirzepatide are glucagon-like peptide-1 (GLP-1) receptor agonists that are effective for weight reduction. Recent reports of patients experiencing suicidal thoughts and other psychiatric adverse events while ... ...

    Abstract Background: Semaglutide, liraglutide and tirzepatide are glucagon-like peptide-1 (GLP-1) receptor agonists that are effective for weight reduction. Recent reports of patients experiencing suicidal thoughts and other psychiatric adverse events while using GLP-1 agonists have raised concerns about the potential risk of self-harm and led the European Medicines Agency to investigate these medications.
    Aim: To identify and analyse the psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide.
    Method: All individual case safety reports for semaglutide, liraglutide, and tirzepatide reported to the EudraVigilance database from 01/01/2021 to 30/05/2023 were analysed. Descriptive statistics were used to explore study population characteristics.
    Results: During the study period, 31,444 adverse event reports were identified: semaglutide (n = 13,956; 44.4%), liraglutide (n = 16,748; 53.2%), and tirzepatide (n = 740; 2.3%). There were 372 reports with psychiatric adverse event reports (n = 372; 1.18%) with a total of 481 adverse events. Women accounted for 65% (n = 242) of these reports. Depression was the most commonly reported adverse event (n = 187; 50.3%), followed by anxiety (n = 144; 38.7%) and suicidal ideation (n = 73; 19.6%). Nine deaths (8 with liraglutide and 1 with semaglutide) and 11 life-threatening outcomes (4 associated with liraglutide and 7 with semaglutide) were reported. The fatal outcomes occurred primarily among men (8 out of 9) resulting from completed suicidal attempts and depression.
    Conclusion: Psychiatric adverse events comprised only 1.2% of the total reports for semaglutide, liraglutide, and tirzepatide. However, the severity and fatal outcomes of some of these reports warrant further investigation.
    MeSH term(s) Male ; Humans ; Female ; Liraglutide/adverse effects ; Hypoglycemic Agents/adverse effects ; Diabetes Mellitus, Type 2/drug therapy ; Pharmacovigilance ; Glucagon-Like Peptide-1 Receptor/agonists ; Glucagon-Like Peptide-1 Receptor/therapeutic use ; Glucagon-Like Peptide-2 Receptor ; Glucagon-Like Peptides ; Gastric Inhibitory Polypeptide
    Chemical Substances Liraglutide (839I73S42A) ; Hypoglycemic Agents ; semaglutide (53AXN4NNHX) ; tirzepatide (OYN3CCI6QE) ; Glucagon-Like Peptide-1 Receptor ; Glucagon-Like Peptide-2 Receptor ; Glucagon-Like Peptides (62340-29-8) ; Gastric Inhibitory Polypeptide (59392-49-3)
    Language English
    Publishing date 2024-01-24
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2601204-2
    ISSN 2210-7711 ; 2210-7703 ; 0928-1231
    ISSN (online) 2210-7711
    ISSN 2210-7703 ; 0928-1231
    DOI 10.1007/s11096-023-01694-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database.

    Tobaiqy, Mansour / Elkout, Hajer / MacLure, Katie

    Vaccines

    2021  Volume 9, Issue 4

    Abstract: The development of safe, effective, affordable vaccines against COVID-19 remains the cornerstone to mitigating this pandemic. Early in December 2020, multiple research groups had designed potential vaccines. From 11 March 2021, several European countries ...

    Abstract The development of safe, effective, affordable vaccines against COVID-19 remains the cornerstone to mitigating this pandemic. Early in December 2020, multiple research groups had designed potential vaccines. From 11 March 2021, several European countries temporarily suspended the use of the Oxford-AstraZeneca vaccine amid reports of blood clot events and the death of a vaccinated person, despite the European Medicines Agency (EMA) and the World Health Organization's assurance that there was no indication that vaccination was linked. This study aimed to identify and analyse the thrombotic adverse reactions associated with the Oxford-AstraZeneca vaccine. This was a retrospective descriptive study using spontaneous reports submitted to the EudraVigilance database in the period from 17 February to 12 March 2021. There were 54,571 adverse reaction reports, of which 28 were associated with thrombotic adverse reactions. Three fatalities were related to pulmonary embolism; one fatality to thrombosis. With 17 million people having had the AstraZeneca vaccine, these are extremely rare events The EMA's Pharmacovigilance Risk Assessment Committee (18 March 2021) concluded that the vaccine was safe, effective and the benefits outweighed the risks. Conducting further analyses based on more detailed thrombotic adverse event reports, including patients' characteristics and comorbidities, may enable assessment of the causality with higher specificity.
    Language English
    Publishing date 2021-04-16
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2703319-3
    ISSN 2076-393X
    ISSN 2076-393X
    DOI 10.3390/vaccines9040393
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database.

    Tobaiqy, Mansour / MacLure, Katie / Elkout, Hajer / Stewart, Derek

    Vaccines

    2021  Volume 9, Issue 11

    Abstract: Vaccination against COVID-19 is the cornerstone of controlling and mitigating the ongoing pandemic. Thrombotic adverse events linked to Moderna, Pfizer and the Oxford-AstraZeneca vaccine have been documented and described as extremely rare. While the ... ...

    Abstract Vaccination against COVID-19 is the cornerstone of controlling and mitigating the ongoing pandemic. Thrombotic adverse events linked to Moderna, Pfizer and the Oxford-AstraZeneca vaccine have been documented and described as extremely rare. While the Oxford-AstraZeneca vaccine has received much of the attention, the other vaccines should not go unchallenged. This study aimed to determine the frequency of reported thrombotic adverse events and clinical outcomes for these three COVID-19 vaccines, namely, Moderna, Pfizer and Oxford-AstraZeneca. A retrospective descriptive analysis was conducted of spontaneous reports for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines submitted to the EudraVigilance database in the period from 17 February to 14 June 2021. There were 729,496 adverse events for the three vaccines, of which 3420 were thrombotic, mainly Oxford-AstraZeneca (n = 1988; 58.1%) followed by Pfizer (n = 1096; 32.0%) and Moderna (n = 336; 9.8%). As serious adverse events, there were 705 reports of pulmonary embolism for the three vaccines, of which 130 reports (18.4%) were for Moderna, 226 reports (32.1%) for Pfizer and 349 (49.5%) for Oxford-AstraZeneca vaccines. The occurrence of pulmonary embolism is significantly associated with a fatal outcome (
    Language English
    Publishing date 2021-11-15
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2703319-3
    ISSN 2076-393X
    ISSN 2076-393X
    DOI 10.3390/vaccines9111326
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine reported to EudraVigilance database

    Tobaiqy, Mansour / Elkout, Hajer / MacLure, Katie

    medRxiv

    Abstract: The development of safe, effective, affordable vaccines against COVID-19 remains the cornerstone to mitigating this pandemic. Early December 2020, multiple research groups had designed potential vaccines. From 11 March 2021, several European countries ... ...

    Abstract The development of safe, effective, affordable vaccines against COVID-19 remains the cornerstone to mitigating this pandemic. Early December 2020, multiple research groups had designed potential vaccines. From 11 March 2021, several European countries temporarily suspended the use of the Oxford-AstraZeneca vaccine amid reports of blood clot events and death of a vaccinated person, despite the European Medicines Agency and the World Health Organization assurance that there was no indication that vaccination was linked. This study aimed to identify and analyse the thrombotic adverse reactions associated with Oxford-AstraZeneca vaccine. This was a retrospective descriptive study using spontaneous reports submitted to the EudraVigilance database in the period from 17 February to 12 March 2021. There were 54,571 adverse reaction reports of which 28 were associated with thrombotic adverse reactions. Three fatalities were related to Pulmonary Embolism and 1 fatality to Thrombosis. With 17 million people having had the AstraZeneca vaccine, these are extremely rare events. The EMA Pharmacovigilance Risk Assessment Committee (18 March 2021) concluded that the vaccine was safe, effective and the benefits outweighed the risks. Conducting further analyses based on more detailed thrombotic adverse event reports, including patients characteristics and comorbidities, may enable assessment of the causality with higher specificity.
    Keywords covid19
    Language English
    Publishing date 2021-03-20
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.03.19.21253980
    Database COVID19

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Thrombotic adverse events reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database

    Tobaiqy, Mansour / MacLure, Katie / Elkout, Hajer / Stewart, Derek

    medRxiv

    Abstract: Summary Background Vaccination against COVID-19 is the cornerstone to control and mitigate the ongoing pandemic. Thrombotic adverse events linked to Moderna, Pfizer and the Oxford-AstraZeneca vaccine have been documented and described as extremely rare. ... ...

    Abstract Summary Background Vaccination against COVID-19 is the cornerstone to control and mitigate the ongoing pandemic. Thrombotic adverse events linked to Moderna, Pfizer and the Oxford-AstraZeneca vaccine have been documented and described as extremely rare. While the Oxford-AstraZeneca vaccine has received much of the attention, the other vaccines should not go unchallenged. This study aimed to determine the frequency of reported thrombotic adverse events and clinical outcomes for these three COVID-19 vaccines, namely, Moderna, Pfizer and Oxford-AstraZeneca Methods A retrospective descriptive analysis was conducted of spontaneous reports for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines submitted to the EudraVigilance database in the period from 17 February to 14 June 2021. Findings There were 729,496 adverse events for the three vaccines, of which 3,420 were thrombotic, mainly Oxford-AstraZeneca (n=1,988; 58.1%) followed by Pfizer (n=1,096; 32.0%) and Moderna (n=336; 9.8%). As serious adverse events, there were 705 reports of pulmonary embolism for the three vaccines, of which 130 reports (18.4%) were for Moderna, 226 reports (32.1%) for Pfizer and 349 (49.5%) for Oxford-AstraZeneca vaccines. The occurrence of pulmonary embolism is significantly associated with a fatal outcome (P=<0.001). Sixty-three fatalities were recorded (n=63/3420; 1.8%), of which Moderna (n=6), Pfizer (n=25) and Oxford-AstraZeneca (n=32). Interpretation Thrombotic adverse events reported for the three vaccines remains extremely rare with multiple causative factors reported elsewhere as precipitating these events. Practicing vigilance and proper clinical management for the affected vaccines, as well as continuing to report adverse events, are essential.
    Keywords covid19
    Language English
    Publishing date 2021-09-22
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.09.12.21263462
    Database COVID19

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Adequate levels of adherence with controller medication is associated with increased use of rescue medication in asthmatic children.

    Elkout, Hajer / Helms, Peter J / Simpson, Colin R / McLay, James S

    PloS one

    2012  Volume 7, Issue 6, Page(s) e39130

    Abstract: Background: The role of asthma controller medication adherence and the level of asthma control in children is poorly defined.: Aims: To assess the association between asthma controller medication adherence and asthma control in children using ... ...

    Abstract Background: The role of asthma controller medication adherence and the level of asthma control in children is poorly defined.
    Aims: To assess the association between asthma controller medication adherence and asthma control in children using routinely acquired prescribing data.
    Methods: A retrospective observational study of children aged 0-18 years prescribed inhaled corticosteroids only (ICS), leukotriene receptors antagonists (LTRA), or long-acting β2 agonists (LABA) and ICS prescribed as separate or combined inhalers, between 01/09/2001 and 31/08/2006, registered with primary care practices contributing to the Practice Team Information database. The medication possession ratio (MPR) was calculated and associations with asthma control explored. Poor asthma control was defined as the issue of prescriptions for ≥ 1 course of oral corticosteroids (OCS) and/or ≥ 6 short-acting β2 agonists (SABA) canisters annually.
    Results: A total of 3172 children prescribed asthma controller medication were identified. Of these, 15-39% (depending on controller medication) demonstrated adequate MPR. Adequate MPR was associated with male gender, good socio-economic status, and oral LTRA therapy. Adequate MPR was more likely to be associated with increased use of rescue medication. However logistic regression only identified a significant relationship for ICS only (odds ratio [OR], 1.89; 95% confidence interval [CI], 1.35-2.48; p<0.001), LTRA (OR, 2.11; 95% CI, 1.27-3.48; p = 0.004) and LABA/ICS (OR, 2.85; 95% CI, 1.62-5.02; p<0.001).
    Conclusion: Poor adherence was observed for all asthma controller medications, although was significantly better for oral LRTA. In this study adequate adherence was not associated with the use of less rescue medication, suggesting that adherence is a complex issue.
    MeSH term(s) Administration, Inhalation ; Administration, Oral ; Adolescent ; Anti-Asthmatic Agents/therapeutic use ; Asthma/drug therapy ; Asthma/prevention & control ; Child ; Child, Preschool ; Drug Combinations ; Female ; Humans ; Infant ; Infant, Newborn ; Male ; Medication Adherence/statistics & numerical data ; Outcome Assessment, Health Care ; Primary Health Care ; Retrospective Studies
    Chemical Substances Anti-Asthmatic Agents ; Drug Combinations
    Language English
    Publishing date 2012-06-27
    Publishing country United States
    Document type Comparative Study ; Journal Article
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0039130
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: Changes in primary care prescribing patterns for paediatric asthma: a prescribing database analysis.

    Elkout, Hajer / Helms, Peter J / Simpson, Colin R / McLay, James S

    Archives of disease in childhood

    2012  Volume 97, Issue 6, Page(s) 521–525

    Abstract: Background: Little is known about the impact of British asthma management guideline revisions. Concerns about the use of high dose inhaled corticosteroids (ICS) in children have resulted in the promotion of add-on therapy.: Aims: To assess ... ...

    Abstract Background: Little is known about the impact of British asthma management guideline revisions. Concerns about the use of high dose inhaled corticosteroids (ICS) in children have resulted in the promotion of add-on therapy.
    Aims: To assess prescribing patterns of asthma medication in children in the primary care setting.
    Methods: Retrospective observational study of asthma prescribing in children aged 0-18 years using primary care database from 2001 to 2006.
    Results: The proportion of children prescribed oral corticosteroids increased significantly (from 6% in 2001-2002 to 16% in 2005-2006, p<0.001), while the proportion of children prescribed an ICS dose of >400 mcg decreased from 16.2% to 11.7% (P<0.001). The proportion of children prescribed an add-on therapy and an ICS dose >400 µg, increased from 38.8 % in 2001-2002 to 61.2% in 2005-2006 (p<0.001).
    Conclusions: Although adherence with asthma management guidelines is not optimal, this study has identified improved adherence in primary care.
    MeSH term(s) Administration, Oral ; Adolescent ; Adrenal Cortex Hormones/administration & dosage ; Adrenal Cortex Hormones/therapeutic use ; Anti-Asthmatic Agents/administration & dosage ; Anti-Asthmatic Agents/therapeutic use ; Asthma/drug therapy ; Child ; Child, Preschool ; Drug Therapy, Combination ; Female ; Guideline Adherence ; Humans ; Infant ; Infant, Newborn ; Male ; Pediatrics ; Practice Guidelines as Topic ; Practice Patterns, Physicians'/trends ; Primary Health Care ; Retrospective Studies
    Chemical Substances Adrenal Cortex Hormones ; Anti-Asthmatic Agents
    Language English
    Publishing date 2012-06
    Publishing country England
    Document type Journal Article
    ZDB-ID 524-1
    ISSN 1468-2044 ; 0003-9888 ; 1359-2998
    ISSN (online) 1468-2044
    ISSN 0003-9888 ; 1359-2998
    DOI 10.1136/adc.2010.206268
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Um IV Zs.106: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MA 3: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.

    Fitzmaurice, Christina / Abate, Degu / Abbasi, Naghmeh / Abbastabar, Hedayat / Abd-Allah, Foad / Abdel-Rahman, Omar / Abdelalim, Ahmed / Abdoli, Amir / Abdollahpour, Ibrahim / Abdulle, Abdishakur S M / Abebe, Nebiyu Dereje / Abraha, Haftom Niguse / Abu-Raddad, Laith Jamal / Abualhasan, Ahmed / Adedeji, Isaac Akinkunmi / Advani, Shailesh M / Afarideh, Mohsen / Afshari, Mahdi / Aghaali, Mohammad /
    Agius, Dominic / Agrawal, Sutapa / Ahmadi, Ayat / Ahmadian, Elham / Ahmadpour, Ehsan / Ahmed, Muktar Beshir / Akbari, Mohammad Esmaeil / Akinyemiju, Tomi / Al-Aly, Ziyad / AlAbdulKader, Assim M / Alahdab, Fares / Alam, Tahiya / Alamene, Genet Melak / Alemnew, Birhan Tamene T / Alene, Kefyalew Addis / Alinia, Cyrus / Alipour, Vahid / Aljunid, Syed Mohamed / Bakeshei, Fatemeh Allah / Almadi, Majid Abdulrahman Hamad / Almasi-Hashiani, Amir / Alsharif, Ubai / Alsowaidi, Shirina / Alvis-Guzman, Nelson / Amini, Erfan / Amini, Saeed / Amoako, Yaw Ampem / Anbari, Zohreh / Anber, Nahla Hamed / Andrei, Catalina Liliana / Anjomshoa, Mina / Ansari, Fereshteh / Ansariadi, Ansariadi / Appiah, Seth Christopher Yaw / Arab-Zozani, Morteza / Arabloo, Jalal / Arefi, Zohreh / Aremu, Olatunde / Areri, Habtamu Abera / Artaman, Al / Asayesh, Hamid / Asfaw, Ephrem Tsegay / Ashagre, Alebachew Fasil / Assadi, Reza / Ataeinia, Bahar / Atalay, Hagos Tasew / Ataro, Zerihun / Atique, Suleman / Ausloos, Marcel / Avila-Burgos, Leticia / Avokpaho, Euripide F G A / Awasthi, Ashish / Awoke, Nefsu / Ayala Quintanilla, Beatriz Paulina / Ayanore, Martin Amogre / Ayele, Henok Tadesse / Babaee, Ebrahim / Bacha, Umar / Badawi, Alaa / Bagherzadeh, Mojtaba / Bagli, Eleni / Balakrishnan, Senthilkumar / Balouchi, Abbas / Bärnighausen, Till Winfried / Battista, Robert J / Behzadifar, Masoud / Behzadifar, Meysam / Bekele, Bayu Begashaw / Belay, Yared Belete / Belayneh, Yaschilal Muche / Berfield, Kathleen Kim Sachiko / Berhane, Adugnaw / Bernabe, Eduardo / Beuran, Mircea / Bhakta, Nickhill / Bhattacharyya, Krittika / Biadgo, Belete / Bijani, Ali / Bin Sayeed, Muhammad Shahdaat / Birungi, Charles / Bisignano, Catherine / Bitew, Helen / Bjørge, Tone / Bleyer, Archie / Bogale, Kassawmar Angaw / Bojia, Hunduma Amensisa / Borzì, Antonio M / Bosetti, Cristina / Bou-Orm, Ibrahim R / Brenner, Hermann / Brewer, Jerry D / Briko, Andrey Nikolaevich / Briko, Nikolay Ivanovich / Bustamante-Teixeira, Maria Teresa / Butt, Zahid A / Carreras, Giulia / Carrero, Juan J / Carvalho, Félix / Castro, Clara / Castro, Franz / Catalá-López, Ferrán / Cerin, Ester / Chaiah, Yazan / Chanie, Wagaye Fentahun / Chattu, Vijay Kumar / Chaturvedi, Pankaj / Chauhan, Neelima Singh / Chehrazi, Mohammad / Chiang, Peggy Pei-Chia / Chichiabellu, Tesfaye Yitna / Chido-Amajuoyi, Onyema Greg / Chimed-Ochir, Odgerel / Choi, Jee-Young J / Christopher, Devasahayam J / Chu, Dinh-Toi / Constantin, Maria-Magdalena / Costa, Vera M / Crocetti, Emanuele / Crowe, Christopher Stephen / Curado, Maria Paula / Dahlawi, Saad M A / Damiani, Giovanni / Darwish, Amira Hamed / Daryani, Ahmad / das Neves, José / Demeke, Feleke Mekonnen / Demis, Asmamaw Bizuneh / Demissie, Birhanu Wondimeneh / Demoz, Gebre Teklemariam / Denova-Gutiérrez, Edgar / Derakhshani, Afshin / Deribe, Kalkidan Solomon / Desai, Rupak / Desalegn, Beruk Berhanu / Desta, Melaku / Dey, Subhojit / Dharmaratne, Samath Dhamminda / Dhimal, Meghnath / Diaz, Daniel / Dinberu, Mesfin Tadese Tadese / Djalalinia, Shirin / Doku, David Teye / Drake, Thomas M / Dubey, Manisha / Dubljanin, Eleonora / Duken, Eyasu Ejeta / Ebrahimi, Hedyeh / Effiong, Andem / Eftekhari, Aziz / El Sayed, Iman / Zaki, Maysaa El Sayed / El-Jaafary, Shaimaa I / El-Khatib, Ziad / Elemineh, Demelash Abewa / Elkout, Hajer / Ellenbogen, Richard G / Elsharkawy, Aisha / Emamian, Mohammad Hassan / Endalew, Daniel Adane / Endries, Aman Yesuf / Eshrati, Babak / Fadhil, Ibtihal / Fallah Omrani, Vahid / Faramarzi, Mahbobeh / Farhangi, Mahdieh Abbasalizad / Farioli, Andrea / Farzadfar, Farshad / Fentahun, Netsanet / Fernandes, Eduarda / Feyissa, Garumma Tolu / Filip, Irina / Fischer, Florian / Fisher, James L / Force, Lisa M / Foroutan, Masoud / Freitas, Marisa / Fukumoto, Takeshi / Futran, Neal D / Gallus, Silvano / Gankpe, Fortune Gbetoho / Gayesa, Reta Tsegaye / Gebrehiwot, Tsegaye Tewelde / Gebremeskel, Gebreamlak Gebremedhn / Gedefaw, Getnet Azeze / Gelaw, Belayneh K / Geta, Birhanu / Getachew, Sefonias / Gezae, Kebede Embaye / Ghafourifard, Mansour / Ghajar, Alireza / Ghashghaee, Ahmad / Gholamian, Asadollah / Gill, Paramjit Singh / Ginindza, Themba T G / Girmay, Alem / Gizaw, Muluken / Gomez, Ricardo Santiago / Gopalani, Sameer Vali / Gorini, Giuseppe / Goulart, Bárbara Niegia Garcia / Grada, Ayman / Ribeiro Guerra, Maximiliano / Guimaraes, Andre Luiz Sena / Gupta, Prakash C / Gupta, Rahul / Hadkhale, Kishor / Haj-Mirzaian, Arvin / Haj-Mirzaian, Arya / Hamadeh, Randah R / Hamidi, Samer / Hanfore, Lolemo Kelbiso / Haro, Josep Maria / Hasankhani, Milad / Hasanzadeh, Amir / Hassen, Hamid Yimam / Hay, Roderick J / Hay, Simon I / Henok, Andualem / Henry, Nathaniel J / Herteliu, Claudiu / Hidru, Hagos D / Hoang, Chi Linh / Hole, Michael K / Hoogar, Praveen / Horita, Nobuyuki / Hosgood, H Dean / Hosseini, Mostafa / Hosseinzadeh, Mehdi / Hostiuc, Mihaela / Hostiuc, Sorin / Househ, Mowafa / Hussen, Mohammedaman Mama / Ileanu, Bogdan / Ilic, Milena D / Innos, Kaire / Irvani, Seyed Sina Naghibi / Iseh, Kufre Robert / Islam, Sheikh Mohammed Shariful / Islami, Farhad / Jafari Balalami, Nader / Jafarinia, Morteza / Jahangiry, Leila / Jahani, Mohammad Ali / Jahanmehr, Nader / Jakovljevic, Mihajlo / James, Spencer L / Javanbakht, Mehdi / Jayaraman, Sudha / Jee, Sun Ha / Jenabi, Ensiyeh / Jha, Ravi Prakash / Jonas, Jost B / Jonnagaddala, Jitendra / Joo, Tamas / Jungari, Suresh Banayya / Jürisson, Mikk / Kabir, Ali / Kamangar, Farin / Karch, André / Karimi, Narges / Karimian, Ansar / Kasaeian, Amir / Kasahun, Gebremicheal Gebreslassie / Kassa, Belete / Kassa, Tesfaye Dessale / Kassaw, Mesfin Wudu / Kaul, Anil / Keiyoro, Peter Njenga / Kelbore, Abraham Getachew / Kerbo, Amene Abebe / Khader, Yousef Saleh / Khalilarjmandi, Maryam / Khan, Ejaz Ahmad / Khan, Gulfaraz / Khang, Young-Ho / Khatab, Khaled / Khater, Amir / Khayamzadeh, Maryam / Khazaee-Pool, Maryam / Khazaei, Salman / Khoja, Abdullah T / Khosravi, Mohammad Hossein / Khubchandani, Jagdish / Kianipour, Neda / Kim, Daniel / Kim, Yun Jin / Kisa, Adnan / Kisa, Sezer / Kissimova-Skarbek, Katarzyna / Komaki, Hamidreza / Koyanagi, Ai / Krohn, Kristopher J / Bicer, Burcu Kucuk / Kugbey, Nuworza / Kumar, Vivek / Kuupiel, Desmond / La Vecchia, Carlo / Lad, Deepesh P / Lake, Eyasu Alem / Lakew, Ayenew Molla / Lal, Dharmesh Kumar / Lami, Faris Hasan / Lan, Qing / Lasrado, Savita / Lauriola, Paolo / Lazarus, Jeffrey V / Leigh, James / Leshargie, Cheru Tesema / Liao, Yu / Limenih, Miteku Andualem / Listl, Stefan / Lopez, Alan D / Lopukhov, Platon D / Lunevicius, Raimundas / Madadin, Mohammed / Magdeldin, Sameh / El Razek, Hassan Magdy Abd / Majeed, Azeem / Maleki, Afshin / Malekzadeh, Reza / Manafi, Ali / Manafi, Navid / Manamo, Wondimu Ayele / Mansourian, Morteza / Mansournia, Mohammad Ali / Mantovani, Lorenzo Giovanni / Maroufizadeh, Saman / Martini, Santi Martini S / Mashamba-Thompson, Tivani Phosa / Massenburg, Benjamin Ballard / Maswabi, Motswadi Titus / Mathur, Manu Raj / McAlinden, Colm / McKee, Martin / Meheretu, Hailemariam Abiy Alemu / Mehrotra, Ravi / Mehta, Varshil / Meier, Toni / Melaku, Yohannes A / Meles, Gebrekiros Gebremichael / Meles, Hagazi Gebre / Melese, Addisu / Melku, Mulugeta / Memiah, Peter T N / Mendoza, Walter / Menezes, Ritesh G / Merat, Shahin / Meretoja, Tuomo J / Mestrovic, Tomislav / Miazgowski, Bartosz / Miazgowski, Tomasz / Mihretie, Kebadnew Mulatu M / Miller, Ted R / Mills, Edward J / Mir, Seyed Mostafa / Mirzaei, Hamed / Mirzaei, Hamid Reza / Mishra, Rashmi / Moazen, Babak / Mohammad, Dara K / Mohammad, Karzan Abdulmuhsin / Mohammad, Yousef / Darwesh, Aso Mohammad / Mohammadbeigi, Abolfazl / Mohammadi, Hiwa / Mohammadi, Moslem / Mohammadian, Mahdi / Mohammadian-Hafshejani, Abdollah / Mohammadoo-Khorasani, Milad / Mohammadpourhodki, Reza / Mohammed, Ammas Siraj / Mohammed, Jemal Abdu / Mohammed, Shafiu / Mohebi, Farnam / Mokdad, Ali H / Monasta, Lorenzo / Moodley, Yoshan / Moosazadeh, Mahmood / Moossavi, Maryam / Moradi, Ghobad / Moradi-Joo, Mohammad / Moradi-Lakeh, Maziar / Moradpour, Farhad / Morawska, Lidia / Morgado-da-Costa, Joana / Morisaki, Naho / Morrison, Shane Douglas / Mosapour, Abbas / Mousavi, Seyyed Meysam / Muche, Achenef Asmamaw / Muhammed, Oumer Sada S / Musa, Jonah / Nabhan, Ashraf F / Naderi, Mehdi / Nagarajan, Ahamarshan Jayaraman / Nagel, Gabriele / Nahvijou, Azin / Naik, Gurudatta / Najafi, Farid / Naldi, Luigi / Nam, Hae Sung / Nasiri, Naser / Nazari, Javad / Negoi, Ionut / Neupane, Subas / Newcomb, Polly A / Nggada, Haruna Asura / Ngunjiri, Josephine W / Nguyen, Cuong Tat / Nikniaz, Leila / Ningrum, Dina Nur Anggraini / Nirayo, Yirga Legesse / Nixon, Molly R / Nnaji, Chukwudi A / Nojomi, Marzieh / Nosratnejad, Shirin / Shiadeh, Malihe Nourollahpour / Obsa, Mohammed Suleiman / Ofori-Asenso, Richard / Ogbo, Felix Akpojene / Oh, In-Hwan / Olagunju, Andrew T / Olagunju, Tinuke O / Oluwasanu, Mojisola Morenike / Omonisi, Abidemi E / Onwujekwe, Obinna E / Oommen, Anu Mary / Oren, Eyal / Ortega-Altamirano, Doris D V / Ota, Erika / Otstavnov, Stanislav S / Owolabi, Mayowa Ojo / P A, Mahesh / Padubidri, Jagadish Rao / Pakhale, Smita / Pakpour, Amir H / Pana, Adrian / Park, Eun-Kee / Parsian, Hadi / Pashaei, Tahereh / Patel, Shanti / Patil, Snehal T / Pennini, Alyssa / Pereira, David M / Piccinelli, Cristiano / Pillay, Julian David / Pirestani, Majid / Pishgar, Farhad / Postma, Maarten J / Pourjafar, Hadi / Pourmalek, Farshad / Pourshams, Akram / Prakash, Swayam / Prasad, Narayan / Qorbani, Mostafa / Rabiee, Mohammad / Rabiee, Navid / Radfar, Amir / Rafiei, Alireza / Rahim, Fakher / Rahimi, Mahdi / Rahman, Muhammad Aziz / Rajati, Fatemeh / Rana, Saleem M / Raoofi, Samira / Rath, Goura Kishor / Rawaf, David Laith / Rawaf, Salman / Reiner, Robert C / Renzaho, Andre M N / Rezaei, Nima / Rezapour, Aziz / Ribeiro, Ana Isabel / Ribeiro, Daniela / Ronfani, Luca / Roro, Elias Merdassa / Roshandel, Gholamreza / Rostami, Ali / Saad, Ragy Safwat / Sabbagh, Parisa / Sabour, Siamak / Saddik, Basema / Safiri, Saeid / Sahebkar, Amirhossein / Salahshoor, Mohammad Reza / Salehi, Farkhonde / Salem, Hosni / Salem, Marwa Rashad / Salimzadeh, Hamideh / Salomon, Joshua A / Samy, Abdallah M / Sanabria, Juan / Santric Milicevic, Milena M / Sartorius, Benn / Sarveazad, Arash / Sathian, Brijesh / Satpathy, Maheswar / Savic, Miloje / Sawhney, Monika / Sayyah, Mehdi / Schneider, Ione J C / Schöttker, Ben / Sekerija, Mario / Sepanlou, Sadaf G / Sepehrimanesh, Masood / Seyedmousavi, Seyedmojtaba / Shaahmadi, Faramarz / Shabaninejad, Hosein / Shahbaz, Mohammad / Shaikh, Masood Ali / Shamshirian, Amir / Shamsizadeh, Morteza / Sharafi, Heidar / Sharafi, Zeinab / Sharif, Mehdi / Sharifi, Ali / Sharifi, Hamid / Sharma, Rajesh / Sheikh, Aziz / Shirkoohi, Reza / Shukla, Sharvari Rahul / Si, Si / Siabani, Soraya / Silva, Diego Augusto Santos / Silveira, Dayane Gabriele Alves / Singh, Ambrish / Singh, Jasvinder A / Sisay, Solomon / Sitas, Freddy / Sobngwi, Eugène / Soofi, Moslem / Soriano, Joan B / Stathopoulou, Vasiliki / Sufiyan, Mu'awiyyah Babale / Tabarés-Seisdedos, Rafael / Tabuchi, Takahiro / Takahashi, Ken / Tamtaji, Omid Reza / Tarawneh, Mohammed Rasoul / Tassew, Segen Gebremeskel / Taymoori, Parvaneh / Tehrani-Banihashemi, Arash / Temsah, Mohamad-Hani / Temsah, Omar / Tesfay, Berhe Etsay / Tesfay, Fisaha Haile / Teshale, Manaye Yihune / Tessema, Gizachew Assefa / Thapa, Subash / Tlaye, Kenean Getaneh / Topor-Madry, Roman / Tovani-Palone, Marcos Roberto / Traini, Eugenio / Tran, Bach Xuan / Tran, Khanh Bao / Tsadik, Afewerki Gebremeskel / Ullah, Irfan / Uthman, Olalekan A / Vacante, Marco / Vaezi, Maryam / Varona Pérez, Patricia / Veisani, Yousef / Vidale, Simone / Violante, Francesco S / Vlassov, Vasily / Vollset, Stein Emil / Vos, Theo / Vosoughi, Kia / Vu, Giang Thu / Vujcic, Isidora S / Wabinga, Henry / Wachamo, Tesfahun Mulatu / Wagnew, Fasil Shiferaw / Waheed, Yasir / Weldegebreal, Fitsum / Weldesamuel, Girmay Teklay / Wijeratne, Tissa / Wondafrash, Dawit Zewdu / Wonde, Tewodros Eshete / Wondmieneh, Adam Belay / Workie, Hailemariam Mekonnen / Yadav, Rajaram / Yadegar, Abbas / Yadollahpour, Ali / Yaseri, Mehdi / Yazdi-Feyzabadi, Vahid / Yeshaneh, Alex / Yimam, Mohammed Ahmed / Yimer, Ebrahim M / Yisma, Engida / Yonemoto, Naohiro / Younis, Mustafa Z / Yousefi, Bahman / Yousefifard, Mahmoud / Yu, Chuanhua / Zabeh, Erfan / Zadnik, Vesna / Moghadam, Telma Zahirian / Zaidi, Zoubida / Zamani, Mohammad / Zandian, Hamed / Zangeneh, Alireza / Zaki, Leila / Zendehdel, Kazem / Zenebe, Zerihun Menlkalew / Zewale, Taye Abuhay / Ziapour, Arash / Zodpey, Sanjay / Murray, Christopher J L

    JAMA oncology

    2019  Volume 5, Issue 12, Page(s) 1749–1768

    Abstract: Importance: Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting ... ...

    Abstract Importance: Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data.
    Objective: To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning.
    Evidence review: We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence.
    Findings: In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572 000 deaths and 15.2 million DALYs), and stomach cancer (542 000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819 000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601 000 deaths and 17.4 million DALYs), TBL cancer (596 000 deaths and 12.6 million DALYs), and colorectal cancer (414 000 deaths and 8.3 million DALYs).
    Conclusions and relevance: The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care.
    MeSH term(s) Disabled Persons ; Global Burden of Disease ; Global Health ; Humans ; Incidence ; Neoplasms/epidemiology ; Quality-Adjusted Life Years
    Language English
    Publishing date 2019-11-02
    Publishing country United States
    Document type Journal Article
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2019.2996
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top